DE69918690D1 - Stabile igf/igfbp pharmazeutische formulierungen - Google Patents

Stabile igf/igfbp pharmazeutische formulierungen

Info

Publication number
DE69918690D1
DE69918690D1 DE69918690T DE69918690T DE69918690D1 DE 69918690 D1 DE69918690 D1 DE 69918690D1 DE 69918690 T DE69918690 T DE 69918690T DE 69918690 T DE69918690 T DE 69918690T DE 69918690 D1 DE69918690 D1 DE 69918690D1
Authority
DE
Germany
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
stable igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918690T
Other languages
English (en)
Other versions
DE69918690T2 (de
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69918690D1 publication Critical patent/DE69918690D1/de
Publication of DE69918690T2 publication Critical patent/DE69918690T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69918690T 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen Expired - Lifetime DE69918690T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89062 1993-07-08
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (2)

Publication Number Publication Date
DE69918690D1 true DE69918690D1 (de) 2004-08-19
DE69918690T2 DE69918690T2 (de) 2005-08-18

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918690T Expired - Lifetime DE69918690T2 (de) 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen

Country Status (14)

Country Link
US (2) US6436897B2 (de)
EP (1) EP1082133B1 (de)
JP (1) JP2002516871A (de)
KR (1) KR20010052500A (de)
CN (1) CN1201816C (de)
AT (1) ATE270898T1 (de)
AU (1) AU4326799A (de)
BR (1) BR9910863A (de)
CA (1) CA2330925C (de)
DE (1) DE69918690T2 (de)
ES (1) ES2221456T3 (de)
HK (1) HK1040637B (de)
IL (1) IL139969A0 (de)
WO (1) WO1999062536A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
PL1828225T3 (pl) * 2004-12-24 2011-03-31 Insmed Inc Oczyszczone kompleksy rhIGF-I/rhIGFBP-3 i sposób ich wytwarzania
CA2594580C (en) * 2005-01-25 2013-09-24 Wyeth Research Ireland Limited Method for diafiltration
SI1861116T1 (sl) * 2005-03-25 2015-12-31 Regeneron Pharmaceuticals, Inc. Formulacije antagonistov VEGF
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
EP2029103A2 (de) 2006-06-16 2009-03-04 Regeneron Pharmaceuticals, Inc. Vegf-antagonisten-formulierungen zur intravitrealen verabreichung
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0715754A2 (pt) 2006-08-31 2013-07-09 Hoffmann La Roche mÉtodo para a produÇço de fator do crescimento similar Á insulina i
ES2688721T3 (es) 2007-11-01 2018-11-06 Astellas Pharma Inc. Polipéptidos y ácidos nucleicos inmunosupresores
EP2352514A4 (de) * 2008-10-29 2012-07-25 Univ Rockefeller Verfahren und kits zur krankheitsbehandlung durch verabreichung des einen insulinähnlichen wachstumsfaktor bindenden proteins 2
CA2781474C (en) 2009-11-30 2019-06-18 Queensland University Of Technology Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
EP2810070B1 (de) * 2012-02-03 2020-04-01 Charm Sciences Inc. Extraktion von mykotoxinen
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
WO2016209773A1 (en) * 2015-06-22 2016-12-29 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
SMT202300314T1 (it) 2015-12-03 2023-11-13 Regeneron Pharma Metodi di associazione di varianti genetiche con esito clinico in pazienti affetti da degenerazione maculare senile trattati con anti-vegf
US20190018025A1 (en) 2015-12-31 2019-01-17 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11351256B2 (en) 2016-10-07 2022-06-07 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
PT4228676T (pt) * 2020-10-19 2025-01-24 Oak Hill Bio Ltd Composições adequadas para utilização em recém-nascidos
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
DE69434403T2 (de) 1993-09-20 2006-05-04 Celtrix Pharmaceuticals, Inc. Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
AU693489B2 (en) 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
WO1999062536A3 (en) 2000-03-30
EP1082133A2 (de) 2001-03-14
WO1999062536A2 (en) 1999-12-09
CA2330925C (en) 2010-02-09
AU4326799A (en) 1999-12-20
DE69918690T2 (de) 2005-08-18
JP2002516871A (ja) 2002-06-11
CN1201816C (zh) 2005-05-18
HK1040637A1 (en) 2002-06-21
IL139969A0 (en) 2002-02-10
BR9910863A (pt) 2002-06-11
HK1040637B (zh) 2006-01-06
ES2221456T3 (es) 2004-12-16
US20030087806A1 (en) 2003-05-08
ATE270898T1 (de) 2004-07-15
US6436897B2 (en) 2002-08-20
CN1315868A (zh) 2001-10-03
EP1082133B1 (de) 2004-07-14
US20020004478A1 (en) 2002-01-10
CA2330925A1 (en) 1999-12-09
KR20010052500A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
DE69918690D1 (de) Stabile igf/igfbp pharmazeutische formulierungen
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
DK2130554T3 (da) Albuminfrie faktor VIII-præparater
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR9713866A (pt) Composição farmacéutica
EE9700363A (et) Uus anesteseeriva toimega farmatseutiline segu
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
ATE280583T1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DK1131331T3 (da) 13-leddede azalider og deres anvendelse som antibiotiske midler
SE9702680D0 (sv) New formulation
DK0759775T3 (da) Flydende IFN-beta-formuleringer
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
NZ511445A (en) Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
SE9604795D0 (sv) New pharmaceutical formulation
FI933719L (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
SE9604752D0 (sv) Formulation and use
DE69703308D1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
TR200003521T2 (tr) Yeniden-kombine-edilen insan interferonu beta-1a (IFN-beta-1a) formülasyonu.
TR199900748A2 (xx) Osteinduktif protein ve dorsalize faktörünün kombinasyonunun kullanılması.
MX9702899A (es) Compuestos y composiciones para suministrar agentes activos.
DK0983087T3 (da) Multivalent vaccinesammensætning med blandet bærer
IT237618Y1 (it) Struttura di agenda,ad elevata praticita' di impiego

Legal Events

Date Code Title Description
8364 No opposition during term of opposition